Summary & Overview
HCPCS S0119: Ondansetron Oral 4 mg, Antiemetic
HCPCS Level II code S0119 denotes oral ondansetron 4 mg, an antiemetic formulation commonly used to prevent or treat nausea and vomiting in outpatient and ambulatory care. Nationally, clear coding for oral ondansetron is important for consistent billing, benefit determinations, and Medicare-aligned reporting when Q-code pathways apply. This code matters for clinicians, billing staff, and payers because ondansetron is frequently prescribed across specialties and encounters where oral administration is preferred.
Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical purpose and typical sites of service, plus national benchmarking context. The publication outlines expected payer coverage patterns, common billing modifiers and implementation considerations, and where Medicare-specific guidance may affect coding choices. It also highlights which elements are unavailable in the provided input and where to seek supplemental payer-specific policy citations.
This summary is written for a national audience and focuses on the administrative and clinical context of HCPCS Level II code S0119, helping stakeholders understand how the code is used and what to expect when submitting claims for oral ondansetron 4 mg.
Billing Code Overview
HCPCS Level II code S0119 represents ondansetron, oral, 4 mg intended for use in settings that fall under the Medicare statute where the HCPCS Q-code pathway may apply. The service type is oral antiemetic medication administration/supply, and the typical site of service is outpatient or ambulatory settings where oral medications are dispensed or administered, including clinics, physician offices, and outpatient infusion/therapy centers.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult outpatient receiving an oral antiemetic for acute nausea and vomiting related to chemotherapy, radiotherapy, postoperative status, gastroenteritis, or medication-induced nausea. A patient presents to an oncology infusion center or outpatient clinic reporting moderate to severe nausea after chemotherapy infusion. The clinician assesses symptoms, documents indication and prior antiemetic use, and dispenses a single-dose oral tablet of ondansetron S0119 (ondansetron, oral, 4 mg) to be taken immediately and/or as a short course at home. The service is commonly billed by outpatient clinics, physician offices, ambulatory surgical centers, and oncology infusion centers. Typical workflow steps: patient assessment and vital signs; review of medication allergies and interactions; clinician or pharmacist prepares and dispenses/labels the medication; counseling on dose, timing, and side effects is provided; documentation of administration or dispensing and rationale is entered into the medical record. In Medicare-covered circumstances where a Q-code is applicable, billing follows the Medicare statute guidance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
23 | Unusual Anesthesia | Use when general anesthesia is administered for a procedure associated with antiemetic use where anesthesia was significant and not part of the standard procedure. |